Non-profit organisation Myeloma UK has initiated an MUK nine clinical trial that will use genetic techniques to stratify therapy for high-risk myeloma patients in the country.

Designed to focus on the sub-group of patients in urgent need for better outcomes, the trial will identify potentially the best treatment for these patients.

The two-part trial will provide access to diagnostics and genetic profiling developed at the Institute of Cancer Research (ICR) in London through research partly funded by Myeloma UK.

The MUK nine A part of the trial will involve screening of 700 newly diagnosed patients at the ICR using genetic analysis of bone marrow samples, and those determined as high risk will be recruited for the MUK nine B part.

The Phase II MUK nine B will evaluate the effectiveness of a combination of bortezomib (Velcade), lenalidomide (Revlimid), daratumumab (Darzalex), dexamethasone and cyclophosphamide administered along with high-dose therapy and stem cell transplantation.

Additionally, the trial will identify disease markers for myeloma to aid the development of stratified medicine for other sub-groups of the disease.

“The MUK nine trial will give patients access to innovative new treatments and state-of-the-art molecular testing.”

MUK nine chief investigator and ICR senior researcher Dr Martin Kaiser said: “The MUK nine trial will give patients access to innovative new treatments and state-of-the-art molecular testing.

“We hope it will transform myeloma treatment from a one-size fits all approach to a stratified approach driven by disease characteristics.”

The trial is being planned to be conducted at 30 Clinical Trial Network (CTN) centres across the country and will be co-ordinated and sponsored by the University of Leeds’ Clinical Trials Research unit.

Myeloma UK Research director Dr Simon Ridley said: “This trial is looking to the future – we are trying to gain more insight into which treatment combinations might work best in different groups of patients.

“The data this trial will generate can be used in the UK and beyond to support patient access to the most innovative and effective combination treatments.”